

Docket No.: 37998-237330
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Von Der Kammer et al.

Art Unit: Not Yet Assigned

Application No: 10/591,678

Examiner: Not Yet Assigned

Confirmation No: 1407

Filed: September 1, 2006

Atty. Docket No: 37998-237330

For: DIAGNOSTIC AND THERAPEUTIC USE
OF MAL2 GENE AND PROTEIN FOR
NEURODEGENERATIVE DISEASES

Customer No:

26694
PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Documents BA-CD were cited in an International Search Report issued in the parent PCT application. A copy of the International Search Report is attached. Copies of the documents

BA-CD are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO. If a copy of a cited document is desired, please inform the undersigned and a copy of the missing document will be supplied.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237330. A duplicate copy of this paper is enclosed.

Dated: January 25, 2007

Respectfully submitted,

By Kavita B. Lepping
Kavita B. Lepping
Registration No.: 54,262
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/591,678	
			Filing Date	September 1, 2006	
			First Named Inventor	Heinz Von Der Kammer	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	37998-237330

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-01/53343 A	07-26-2001	Human Genome Sciences, Inc.		
	BB	WO-01/36440 A	05-25-2001	Human Genome Sciences, Inc.		
	BC	WO-02/071928	09-19-2002	Millennium Pharmaceuticals, Inc.		
	BD	WO-01/77137 A	10-18-2001	Human Genome Sciences, Inc.		
	BE	WO-02/070539	09-12-2002	Hyseq, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Marazuela, Monica et al., "Expression and Distribution of MAL2, an Essential Element of the Machinery for Basolateral-to-Apical Transcytosis, in Human Thyroid Epithelial Cells," ENDOCRINOLOGY, vol. 145, no. 2, February 2004, pgs. 1011-1016	
	CB	Wilson, S. H. D., et al., "Identification of MAL2, a Novel Member of the MAL Proteolipid Family, Through Interactions with TPD52-like Proteins in the Yeast Two-Hybrid System," GENOMICS, ACADEMIC PRESS, vol. 76, no. 1-3, August 2001, pgs. 81-88	
	CC	Eckelman, William C., "The Use of PET and Knockout Mice in the Drug Discovery Process," DRUG DISCOVERY TODAY, May 1, 2003, vol. 8, no. 9, pgs. 404-410	
	CD	Huse, J. T. et al., "Neurotoxic Traffic: Uncovering the Mechanics of Amyloid Production in Alzheimer's Disease," TRAFFIC, Feb. 2001, vol. 2, no. 2, February 2001, pgs. 75-81	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--